TGFB1 and neoplasm: Although inhibiting only one isoform may not be sufficient to achieve antitumor efficacy, we hypothesized that targeting TGF-β1 would be sufficient to obtain tumor responses, because it is the most prevalent ligand in plasma or serum of patients with invasive metastatic disease and correlates with adverse outcomes (8–22).